

# Cervical Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C9EBF9BA466EN.html>

Date: May 2020

Pages: 1460

Price: US\$ 2,500.00 (Single User License)

ID: C9EBF9BA466EN

## Abstracts

Cervical Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer – Pipeline Review, H1 2020, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 80, 75, 4, 46, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 2, 12 and 4 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on

mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Cervical Cancer - Overview

Cervical Cancer - Therapeutics Development

Cervical Cancer - Therapeutics Assessment

Cervical Cancer - Companies Involved in Therapeutics Development

Cervical Cancer - Drug Profiles

Cervical Cancer - Dormant Projects

Cervical Cancer - Discontinued Products

Cervical Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Cervical Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),  
H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Cervical Cancer - Pipeline by 3SBio Inc, H1 2020  
Cervical Cancer - Pipeline by Aadi Bioscience Inc, H1 2020  
Cervical Cancer - Pipeline by AbbVie Inc, H1 2020  
Cervical Cancer - Pipeline by Abion Inc, H1 2020  
Cervical Cancer - Dormant Projects, H1 2020  
Cervical Cancer - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Cervical Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

3SBio Inc  
Aadi Bioscience Inc  
AbbVie Inc  
Abion Inc  
Abivax SA  
Admedus Ltd  
Advaxis Inc  
Advenchen Laboratories LLC  
Adze Biotechnology Inc  
Affimed GmbH  
Agenus Inc  
Akeso Inc  
Almac Discovery Ltd  
Alphamab Oncology  
amcure GmbH  
Andes Biotechnologies  
Anew Oncology Inc  
AntiCancer Inc  
Apimeds Inc  
Apollomics Inc  
Apotex Inc

Asana BioSciences LLC  
Ascenta Therapeutics Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Bayer AG  
BeiGene Ltd  
Beijing Neoantigen Biotechnology Co Ltd  
Beijing Recreation Guards Biotechnology Co Ltd  
BioAtla LLC  
Biocad  
BIOCND Inc  
Biocon Ltd  
BioIntegrator Ltd  
Bioleaders Corp  
Biomics Biotechnologies Co Ltd  
BioNTech SE  
Boehringer Ingelheim International GmbH  
Boston Biomedical Inc  
Bristol-Myers Squibb Co  
Celleron Therapeutics Ltd  
Cellestia Biotech AG  
Cellid Co Ltd  
Centus Biotherapeutics Ltd  
Changchun Bcht Biotechnology Co Ltd  
Chineo Med Beijing Co Ltd  
Chong Kun Dang Pharmaceutical Corp  
Clovis Oncology Inc  
Convert Pharmaceuticals SA  
Corvus Pharmaceuticals Inc  
Cotinga Pharmaceuticals Inc  
Cue Biopharma Inc  
Cytocom Inc  
CytomX Therapeutics Inc  
CZ BioMed Corp  
Daewon Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
DeMar Pharmaceuticals Inc  
Disulfican Ltd  
EirGenix Inc

Eisai Co Ltd  
Eli Lilly and Co  
Epygen Biotech Pvt Ltd  
Ervaxx Ltd  
Etna Biotech Srl  
Etubics Corp  
Eubiologics Co Ltd  
Exelixis Inc  
EyeGene Inc  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
Five Prime Therapeutics Inc  
Flow Pharma Inc  
Fujifilm Holdings Corp  
GamaMabs Pharma SA  
Gene Techno Science Co Ltd  
Genentech Inc  
Genetic Immunity Inc  
Genexine Inc  
Genmab AS  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
GlycoNex Inc  
Glycostem Therapeutics BV  
GlyTR Therapeutics Inc  
GO Therapeutics Inc  
Gradalis Inc  
Hamlet Pharma AB  
Harbin Gloria Pharmaceuticals Co Ltd  
Hefei Ruichengsheng Biotechnology Co Ltd  
Hookipa Pharma Inc  
Huabo Biopharm Co Ltd  
ImCheck Therapeutics SAS  
Immune Therapeutics Inc  
Immunitor Inc  
ImmunityBio Inc  
Immunomedics Inc  
IMV Inc  
Incyte Corp



Innate Pharma SA  
Innovene  
Innovent Biologics Inc  
InSight Biopharmaceuticals Ltd  
Invectys SA  
Iovance Biotherapeutics Inc  
ISA Pharmaceuticals BV  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
Juno Therapeutics Inc  
Karyopharm Therapeutics Inc  
Komipharm International Co Ltd  
Kymab Ltd  
Medical Guidance Systems LLC  
Merck & Co Inc  
Merck KGaA  
Mereo Biopharma Group Plc  
MicroQuin Ltd  
Midissia Therapeutics Inc  
Molecular Partners AG  
Mundipharma EDO GmbH  
Mycenax Biotech Inc  
NeoTX Therapeutics Ltd  
Newish Technology Beijing Co Ltd  
Novartis AG  
Noyan Pajouhan Biopharma  
Ocellaris Pharma Inc  
Onconova Therapeutics Inc  
OncoSec Medical Inc  
Ono Pharmaceutical Co Ltd  
Oxford Vacmedix UK Ltd  
Pfizer Inc  
Pharma Mar SA  
PharmAbcine Inc  
Phoenix Life Sciences International Ltd  
PI Therapeutics Ltd  
Plus Therapeutics Inc  
Potenza Therapeutics Inc  
Precigen Inc

Prestige BioPharma Pte Ltd  
Puma Biotechnology Inc  
RAPT Therapeutics Inc  
Regeneron Pharmaceuticals Inc  
Rexahn Pharmaceuticals Inc  
Richter Gedeon Nyrt  
Samyang Holdings Corp  
Sanofi  
Savoy Pharmaceuticals Inc  
Seattle Genetics Inc  
Selecta Biosciences Inc  
Shanghai Bovax Biotechnology Co Ltd  
Shanghai Henlius Biotech Inc  
Shanghai Institute of Biological Products Co Ltd  
Shanghai Zerun Biotechnology Co Ltd  
Shantha Biotechnics Pvt Ltd  
Shattuck Labs Inc  
SK Bioscience  
Sorrento Therapeutics Inc  
Sotio AS  
Spring Bank Pharmaceuticals Inc  
SQZ Biotechnologies Co  
Starpharma Holdings Ltd  
Suzhou Stainwei Biotech Inc  
Synermore Biologics Co Ltd  
Takeda Pharmaceutical Co Ltd  
TCRCure Biotech Co Ltd  
Tessa Therapeutics Pte Ltd  
Theralase Technologies Inc  
Theravectys SA  
THEVAX Genetics Vaccine USA Inc  
Transgene SA  
Turnstone Biologics Inc  
Vaccibody AS  
Vascular Biogenics Ltd  
Vectorite Biomedical Inc  
ViciniVax BV  
Vir Biotechnology Inc  
Virion Therapeutics LLC

Virometix AG  
VLP The Vaccines Company SL  
VM Discovery Inc  
Wuhan Binhui Biotechnology Co Ltd  
Xencor Inc  
Xiamen Innovax Biotech Co Ltd  
Zeria Pharmaceutical Co Ltd  
Zhejiang Yangshengtang Biotech Co Ltd  
Zymeworks Inc

## I would like to order

Product name: Cervical Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C9EBF9BA466EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9EBF9BA466EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970